Brii Biosciences Limited (HKG:2137)
1.380
+0.020 (1.45%)
Mar 6, 2026, 4:08 PM HKT
Brii Biosciences Revenue
Brii Biosciences had revenue of 993.00K CNY in the half year ending June 30, 2025, a decrease of -97.52%. This brings the company's revenue in the last twelve months to 28.77M, down -24.18% year-over-year. In the year 2024, Brii Biosciences had annual revenue of 49.94M, down -10.65%.
Revenue (ttm)
28.77M CNY
Revenue Growth
-24.18%
P/S Ratio
31.58
Revenue / Employee
299.73K CNY
Employees
96
Market Cap
995.72M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 49.94M | -5.96M | -10.65% |
| Dec 31, 2023 | 55.89M | -66.39M | -54.29% |
| Dec 31, 2022 | 122.28M | 29.74M | 32.13% |
| Dec 31, 2021 | 92.54M | 10.32M | 12.56% |
| Dec 31, 2020 | 82.22M | 62.02M | 307.10% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 3D Medicines | 491.34M |
| JW (Cayman) Therapeutics Co. | 194.77M |
| Wuhan YZY Biopharma | 163.65M |
| CANbridge Pharmaceuticals | 68.55M |
| Beijing Biostar Pharmaceuticals | 58.66M |
| Kintor Pharmaceutical | 12.04M |
| Transcenta Holding | 10.31M |
| Sunho Biologics | 18.63K |
Brii Biosciences News
- 4 months ago - Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine - PRNewsWire
- 7 months ago - Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results - PRNewsWire
- 8 months ago - Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China - PRNewsWire
- 10 months ago - Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss - PRNewsWire
- 1 year ago - Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification - PRNewsWire
- 1 year ago - Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study - PRNewsWire
- 1 year ago - Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA - PRNewsWire
- 1 year ago - Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024 - PRNewsWire